Stimulation of the Larynx to Treat Unexplained Chronic Cough
Launched by UNIVERSITY OF MINNESOTA · Mar 9, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help people who have a long-lasting cough that doesn’t have a clear cause. Researchers want to see if a device that gently vibrates the larynx (the voice box) can help reduce the severity of these cough symptoms. The trial is currently recruiting participants, and it’s open to adults aged 18 to 88 who have been coughing for more than eight weeks and have a cough severity score of 30 or higher on a scale from 0 to 100.
To participate, individuals need to be able to understand and complete questionnaires in English and provide informed consent. However, those with certain electronic implants, currently undergoing speech therapy for cough, or who do not have regular access to Wi-Fi cannot join. If eligible, participants can expect to try this non-invasive stimulation treatment and share their experiences with the researchers, which could help improve understanding and treatment of unexplained chronic cough in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-88
- • \>8 weeks of cough
- • Cough visual analogue scale (VAS): Rating of 30 or greater on a 0-100 cough severity scale
- • Ability to provide informed consent and independently complete questionnaires
- • Ability to read and speak English
- Exclusion Criteria:
- • Electronic implants (e.g., pacemaker)
- • Currently doing speech therapy for cough
- • Contraindications to safe or effective VTS device use
- • No regular access to wifi internet Neuromuscular impairment that may affect cough/laryngeal sensation and/or function (e.g., multiple system atrophy, Parkinson, CVA, vocal fold paralysis or paresis)
- • Untreated carotid disease
- • BMI \> 40 (for transmission of VTS through soft tissue)
- • Current or recent (quit \< 3 months ago) smoking
- • Known currently infectious cause for cough (e.g., TB, pertussis, COVID)
- • History of known or suspected aspiration pneumonia
- • Diagnosis or clinical suspicion of chronic obstructive pulmonary disease (COPD)
- • Diagnosis or clinical suspicion of interstitial lung disease (ILD)
- • Unmanaged reflux
- • Unmanaged allergies/postnasal drip
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Stephanie Misono
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials